CING
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Cingulate published peer-reviewed data demonstrating the differentiated pharmacokinetic profile of CTx-1301Aug 11, 2026
- Cingulate published Phase 3 ADHD trial results in the Journal of Child and Adolescent PsychopharmacologyJul 31, 2026
- Cingulate was granted its first U.S. patent for ADHD candidate CTx-1301Jun 16, 2026
- Cingulate presents positive Phase 3 results for CTx-1301 demonstrating statistically significant efficacy and entire active-day symptom controlOct 28, 2025
- Cingulate's lead ADHD candidate CTx-1301 selected for podium presentation at AACAP Annual MeetingOct 24, 2025